UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2024
0mins
Source: Globenewswire
Merger and Strategic Focus: Firefly Neuroscience has successfully closed its merger with WaveDancer, which enhances its capacity to commercialize its FDA-cleared Brain Network Analytics (BNA™) technology aimed at improving diagnoses and treatments for mental health disorders.
Partnerships and Future Plans: The company is collaborating with major CNS drug companies like Novartis and Takeda to advance new treatment developments, while also planning to make BNA™ available to neurologists in 2025, leveraging its extensive patient database for better clinical outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
